<i>-Over 3 million Americans have chronic hepatitis C -</i>
-<i>Baby boomers account for 2 of every 3 cases of hepatitis C virus and
vast majority unaware they have this chronic disease </i>-
-<i>Cost burden of hepatitis C to Medicare projected to increase 500% as
baby boomers with HCV age into severe complications of liver disease-</i>
<i><b>-Registration program to evaluate improvements in lung function
(FEV</b></i><sub><i><b>1</b></i></sub><i><b>), restoration of CFTR
activity and safety-</b></i><i><b>-Program designed to support registration in cystic fibrosis
patients with the G551D mutation and to provide first evaluation of
activity in patients with F508del mutations-</b></i><i><b>-Primary endpoint for patients with G551D mutation is improvement
in FEV</b></i><sub><i><b>1 </b></i></sub><i><b>through 24 weeks-</b></i>
CAMBRIDGE, Mass., Jun 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Goldman Sachs 30 th Annual Global Healthcare Conference. Matt Emmens, Chairman, President and Chief Executive Officer of Vertex, will
CAMBRIDGE, Mass., Jun 08, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $103.3 million in aggregate principal amount of those notes for
CAMBRIDGE, Mass., Jun 23, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2009 Piper Jaffray Europe Conference on Tuesday, June 23, 2009 at 4:30 p.m. BST (11:30 a.m. EDT).
CAMBRIDGE, Mass., Jul 07, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Jeffrey Leiden, M.D., Ph.D. and Dennis Winger joined its board of directors. "Jeff and Dennis add tremendous medical and biomedical business perspective to our board.
CAMBRIDGE, Mass., Jul 27, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2009 financial results on Wednesday, August 5, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
<i>-- Vertex to receive $105 million from Mitsubishi following signing,
plus the potential for additional milestones upon commercialization --</i><i>-- Phase 3 registration program for telaprevir in Japan expected to
complete enrollment in the third quarter of 2009 --</i>
